

1 (Revised MS: ENVINT-D-07-00727)

2  
3 **Assessing Inhalatory and Dermal Exposures and Their Resultant Health-Risks for Workers**  
4 **Exposed to Polycyclic Aromatic Hydrocarbons (PAHs) Contained in Oil Mists in a Fastener**  
5 **Manufacturing Industry**

6  
7 Mei-Ru Chen<sup>1</sup>, Ying-Fang Wang<sup>1</sup>, Perng-Jy Tsai<sup>1,2\*</sup>, Wen-Jhy Lee<sup>2,3</sup>

8  
9 <sup>1</sup>*Department of Environmental and Occupational Health, Medical College, National Cheng Kung*  
10 *University. 138, Sheng-Li Rd, Tainan 70428, Taiwan*

11 <sup>2</sup>*Sustainable Environment Research Center, National Cheng Kung University. 1, University Road,*  
12 *Tainan 70101, Taiwan*

13 <sup>3</sup>*Department of Environmental Engineering, National Cheng Kung University, 1 University Road,*  
14 *Tainan 70101, Taiwan*

15  
16  
17  
18 **\*Corresponding author:** Perng-Jy Tsai, Department of Environmental and Occupational Health,  
19 Medical College, National Cheng Kung University. 138, Sheng-Li Road, Tainan 70428, Taiwan.  
20 Tel.: +886-6-2088390; Fax: +886-6-2752484; *E-mail address:* pjtsai@mail.ncku.edu.tw

1 **Abstract**

2 This study first assessed workers' inhalatory and dermal exposures to polycyclic aromatic  
3 hydrocarbon (PAH) contained in oil mists. Then, their resultant lung cancer and skin cancer risks  
4 were estimated. Finally, control strategies were initiated from the health risk management aspect.  
5 All threading workers in a fastener manufacturing plant were included. 16 inhalatory and 88  
6 dermal PAH exposure samples were collected. Results show that the inhalatory gas phase total  
7 PAH exposure level ( $8.60 \times 10^4$  ng/m<sup>3</sup>) was much higher than that of particle phase ( $2.90 \times 10^3$   
8 ng/m<sup>3</sup>). Workers' mean inhalatory exposure level ( $8.83 \times 10^4$  ng/m<sup>3</sup>) was lower, but its  
9 corresponding 1-sided upper 95% confidence level ( $UCL_{1,95\%} = 1.02 \times 10^5$  ng/m<sup>3</sup>) was higher than  
10 the time-weighted average permissible exposure level (PEL-TWA) regulated in Taiwan for PAHs  
11 ( $1.00 \times 10^5$  ng/m<sup>3</sup>). The mean whole body total PAHs dermal exposure levels was  $5.44 \times 10^6$  ng/day  
12 and the top five exposed surface areas were lower arm, hand, upper arm, neck, and head/front. The  
13 estimated lifetime skin cancer risk ( $9.72 \times 10^{-3}$ ) was lower than that of lung cancer risk ( $1.64 \times 10^{-2}$ ),  
14 but both were higher than the significant risk level ( $10^{-3}$ ) defined by the US Supreme Court in  
15 1980. The installation of a local exhaust ventilation system at the threading machine should be  
16 considered as the first priority measurement because both lung and skin cancer risks can be  
17 reduced simultaneously. If the personal protection equipment would be adopted in the future, both  
18 respiratory protection equipment and protective clothing should be used simultaneously.

19 **Keywords:** Polycyclic aromatic hydrocarbons (PAHs); Oil mists; Exposure assessment; Health risk  
20 assessment; Fastener manufacturing industry

## 1 **1. Introduction**

2 Based on the Taiwan governmental statistics in 2002, there were ~1,270 fastener  
3 manufacturing plants and in total employed with ~37,000 employees in the whole country. The  
4 total fastener production rates increased from ~451,000 tons/yr in 1991 to ~1,269,000 tons/yr in  
5 2003 accounting for ~14% world production. The manufacture of fasteners involves seven  
6 important industrial processes, including the wire drawing, forming, threading, cleaning, heat  
7 treatment, surface treatment, and packaging/shipping. Among them, mineral oil-based  
8 metalworking fluids (MWFs) are used in forming, threading, and heat treatment processes for  
9 cooling, lubricating, and corrosion inhibition purposes and hence might result in the emission of  
10 oil mist to the workplace atmosphere and the exposures of workers (Thornburg, 2000; Michalek  
11 et al., 2003). Considering mineral oils are produced by petroleum distillation processes,  
12 semi-volatile organic compounds, such as polycyclic aromatic hydrocarbons (PAHs), are expected  
13 to be contained in emitted oil mists. Epidemiological and animal studies have indicated that oil  
14 mist exposures might result in the laryngeal cancer (Russi et al., 1997), asthma (Robertson et al.,  
15 1988), bronchial hyper-responsiveness (Kennedy et al., 1999), lipoid pneumonia (Cullen et al.,  
16 1981), lung cancer (Kazerouni et al., 2000), and many other respiratory illnesses (Jarvholm et al.,  
17 1982; Massin et al., 1996). Particularly, workers exposed to high airborne concentrations of PAHs  
18 might result in excessive lung cancer rates (Verma et al., 1992; Moulin et al., 1993). In addition,  
19 intensive studies have also reported that all mineral oils are mutagenic to skin because of their  
20 inherent PAH contents (Bingham et al., 1969; Roy et al., 1988; Granella et al., 1995). However, it  
21 should be noted that only very limited studies have been conducted to address workers' dermal  
22 exposures to PAHs (Jongeneelen et al., 1988; Tsai et al., 2001a).

23 In fastener manufacturing industries, workers are exposed to PAHs contained in oil mists via  
24 both inhalatory and dermal exposure routes. Therefore, the present study was set out first to assess  
25 workers' inhalatory and dermal PAH exposures. Then, their resultant lung cancer and skin cancer  
26 risks were estimated. Finally, control strategies were initiated from the health risk management

1 aspect.

## 2 **2. Material and Methods**

### 3 **2.1 Personal inhalable and dermal PAH exposure samplings**

4 For fastener manufacturing industries, the forming, threading, and heat treatment processes  
5 are involved in the use of mineral oil-based MWFs for cooling, lubricating, and corrosion  
6 inhibition purposes. Among them, the threading workers were found with the highest oil mist  
7 exposures in our previous study (Chen et al., 2007), and hence were selected for illustration. All  
8 threading workers were included to conduct personal samplings for assessing their inhalable and  
9 dermal PAH exposures.

10 The sampling method modified from the NIOSH method 5515 was used to assess workers'  
11 inhalatory PAH exposures. The sampling train consisted of a filter cassette (IOM personal  
12 inhalable aerosol sampler, SKC Inc., Catalog No. 225-70) and followed by a sorbent tube  
13 (polyurethane form (PUF) plug/3.5 g ??? (XAD-2) resins/PUF separation layer/0.5 g XAD-2  
14 resin/ PUF plug). The sampling flow rate was specified at 2.0 L/min. Before sampling, all filters  
15 and sorbent tubes were cleaned and extracted with a solvent solution (mixture of n-hexane and  
16 dichloromethane, v:v = 1:1) for 24 hrs in a Soxhlet extractor. Oil mists collected by the IOM  
17 personal sampler were determined by using an electrical balance (Sartorius MP 8-6,  $\pm 0.01$ mg),  
18 then sent to the laboratory, together with the sorbent tube, for PAHs analysis to determine the  
19 concentrations of both particle phase PAHs and gas phase PAHs, respectively. A total of 16  
20 personal inhalable samples (gas+particle phase PAH samples) were collected from this study.

21 The surrogate skin sampling technique was adopted in this study for dermal exposure  
22 assessment. The method was first recognized as a standard method for assessing dermal pesticide  
23 exposures (WHO, 1986; US EPA, 1987), but its use has been extended to assess occupational  
24 exposures to PAHs (Jongeneelen et al., 1988) and dichlorobenzidene (London et al., 1989). A soft  
25 polypropylene with a surface area 100 cm<sup>2</sup> was used as the collecting medium (i.e., exposure pad).  
26 Table 1 shows the 11 sampling body sites and their corresponding surface areas (based on a

1 standard man: height = 173 cm, body weight = 70 kg) for conducting dermal exposure assessment  
2 for each selected worker as recommended by US EPA (US EPA, 1987). However, subjected to  
3 worker's willingness, 11 sampling spots closed to the above mentioned sampling body sites were  
4 chosen for each selected worker (also shown in Table 1). As a result, 88 pad samples were  
5 obtained from this study. Before sampling, all pads were cleaned and extracted with a solvent  
6 solution (mixture of *n*-hexane and dichloromethane, v:v = 1:1) for 24 hrs in a Soxhlet extractor.  
7 Immediately after sampling, the pads were removed, packed in an aluminum foil, and stored at  
8 4°C until analysis.

## 9 **2.2 Sample analyses**

10 For PAHs analyses, all collected samples (including the filter, sorbent tube, and exposure pad)  
11 were placed in a solvent solution (the mixture of *n*-hexane and dichloromethane, v:v = 1:1,  
12 respectively), and extracted in a Soxhlet extractor for 24 hrs. The extract was then concentrated,  
13 cleaned-up and re-concentrated to exactly 1.0mL or 0.5mL. PAH content was determined by  
14 using a gas chromatograph (GC) (Hewlett-Packard 5890A) with a mass selective detector (MSD)  
15 (Hewlett-Packard 5972) and a computer workstation. This GC/MS was equipped with a  
16 Hewlett-Packard capillary column (HP Ultra 2 - 50 m×0.32 mm×0.17 μm), an HP-7673A  
17 automatic sampler, injection volume 1 μL, splitless injection at 310 °C, ion sources temperature at  
18 310 °C, oven temperature from 50 °C to 100 °C at 20 °C/min; 100 °C to 290 °C at 3 °C /min; and  
19 hold at 290 °C for 40 min. The masses of primary and secondary ions of PAHs were determined  
20 using the scan mode for pure PAH standards. Qualification of PAHs was performed using the  
21 selected ion monitoring (SIM) mode (Jongeneelen et al., 1988; Tsai et al., 2001a; Tsai et al.,  
22 2001b; Tsai et al., 2002; Tsai et al., 2004; Li et al., 2003; Lee et al., 2004; Lin et al., 2006; Chen et  
23 al., 2006).

24 The concentrations of 22 PAH compounds were determined, including naphthalene (NaP),  
25 acenaphthylene (AcPy), acenaphthene (AcP), fluorene (Flu), phenanthrene (PA), anthracene (Ant),  
26 fluoranthene (FL), pyrene (Pyr), cyclopenta[*c,d*]pyrene (CYC), benz[*a*]anthracene (BaA),

1 chrysene (CHR), benzo[b]fluoranthene (BbF), benzo[k]fluoranthene (BkF), benz[e]pyrene (BeP),  
2 benzo[a]pyrene (BaP), berylene (PER), indeno[1,2,3-cd]pyrene (IND), dibenz[a,h]anthracene  
3 (DBA), benzo[b]chrycene (BbC), benzo[ghi]perylene (BghiP), coronene (COR) and  
4 dibenzo[a,e]pyrene (DBP). Analysis of the serial dilution of PAH standards show that the limit of  
5 detection (LOD) of GC/MS was 0.093-1.51 ng. Five internal standards (Nap-d8, Acp-d10,  
6 PA-d10, CHR-d12, and PER-d12) were used to check the response factors and recovery  
7 efficiencies for PAHs analysis. The recovery efficiencies of 22 individual PAHs and these five  
8 internal standards were determined by processing a solution containing known PAH  
9 concentrations through the same experimental procedure that used for the analyzing samples. The  
10 recovery efficiency of PAHs varied between 0.786 and 0.935, and averaged 0.865 in this study.  
11 The above values were used to adjust the observed concentration. The mean relative standard  
12 deviation (RSD) (%) of recovery efficiencies was 5.13% (range 1.28-8.89%). The recovery  
13 efficiencies of five internal standards were between 0.791 and 0.986 and were fairly consistent.  
14 The blank tests for PAHs were accomplished by the same procedure as the recovery-efficiency  
15 tests without adding the known standard solution before extraction. Analysis of field blank,  
16 including filters and PUF/resin cartridges, showed no significant contaminant.

## 17 **2.3 Data analysis**

### 18 **2.3.1 Calculating PAH homologue distributions**

19 In this study, the concentration of total PAHs was defined as the sum of the concentrations  
20 of the selected 22 PAH compounds. In addition, PAH contents were further sorted into three  
21 categories according to their molecular weights, including the low molecular weight (LMW-PAHs;  
22 containing two- and three-ringed PAHs), middle molecular weight (MMW-PAHs; containing  
23 four-ringed PAHs), and high molecular weight (HMW-PAHs; containing five-, six- and  
24 seven-ringed PAHs).

### 25 **2.3.2 Calculating BaP equivalent concentrations**

26 Because BaP has been known to be the most carcinogenic PAH compound, the carcinogenic

1 potency of each collected sample was also determined in terms of its BaP equivalent  
 2 concentration (BaP<sub>eq</sub>). The carcinogenic potency of the total PAH exposure could then be  
 3 estimated as the sum of each individual BaP<sub>eq</sub>. To calculate the BaP<sub>eq</sub> for each individual PAH  
 4 species, it requires the use of its toxic equivalent factor (TEF) for the given species relative to BaP  
 5 carcinogenic potency. To date, only a few proposals for TEFs are available (Chu et al., 1984;  
 6 Thorslund et al., 1991; Nisbet et al., 1992). From these, the list of TEFs completed by Nisbet and  
 7 LaGoy (Chu et al., 1984) were adopted in this study (Table 2), as these have been demonstrated to  
 8 be a better reflection of the actual state of knowledge on the toxic potency of each individual PAH  
 9 species relative to BaP (Petry et al., 1996).

### 10 **2.3.3 Calculating personal inhalable and dermal PAH exposure concentrations**

11 In this study, the total inhalatory PAH exposure was defined as the summation of the gas  
 12 phase and particle phase PAH exposures. To estimate a worker's total dermal exposure level, the  
 13 unit dermal surface area PAH exposure level for a given PAH species *i* on the body surface area *j*  
 14 (UDC<sub>ij</sub>; ng/100cm<sup>2</sup>/day) was directly measured from this study. The unit dermal surface area  
 15 PAH exposure level for total PAHs (i.e., the sum of 22 PAH species) for a given body surface  
 16 area *j* (UDE<sub>total,j</sub>; ng/100cm<sup>2</sup>/day) can be determined by using equation 1:

$$17 \quad UDE_{total,j} = \sum_{i=1}^{22} UDC_{ij} \quad (1)$$

18 Dermal PAHs exposure levels for total PAHs at the body surface area *j* (DE<sub>total,j</sub>; ng/day) can be  
 19 determined by equation 2:

$$20 \quad DE_{total,j} = \sum_{i=1}^{22} UDC_{ij} \cdot AD_j \quad (2)$$

21 Where,

22 AD<sub>j</sub>=the corresponding body surface area for the body surface area *j* (unit: 100cm<sup>2</sup>) of a  
 23 standard man (Table 1).

24 Dermal PAH exposure levels for species *i* on the whole body surface area (DE<sub>i,whole</sub>; ng/day) was  
 25 determined by using equation 3:

$$1 \quad DE_{i,whole} = \sum_{j=1}^{11} UDC_{ij} AD_j \quad (3)$$

2 Total dermal PAHs exposure levels on the whole body surface area ( $DE_{total,whole}$ ; ng/day) was  
 3 determined by using equation 4:

$$4 \quad DE_{total,whole} = \sum_{i=1}^{22} \sum_{j=1}^{11} UDC_{ij} AD_j \quad (4)$$

### 5 **2.3.4 Estimating personal inhalable and dermal PAH exposure profiles**

6 In this study, the log-normality of the exposure profile for each exposure group was  
 7 examined by using the W-test (Gilbert, 1987). The arithmetic mean was used to describe the  
 8 average concentration (Rappaport, 1991). The method of the minimum variance unbiased  
 9 estimate (MVUE) was adopted to estimate the arithmetic mean ( $AM_{MVUE}$ ) and its lower and upper  
 10 one-sided 95% confidence intervals ( $LCL_{1,95\%}$  and  $UCL_{1,95\%}$ , respectively). Full calculating  
 11 procedures were described in the study conducted by Attfield and Hewet (1992). The above  
 12 method has also been recommended by the American Industrial Hygiene Association (AIHA)  
 13 Exposure Assessment Strategies Committee for exposure data with various sample sizes and  
 14 geometric standard deviations (GSDs) (Mulhausen and Damiano, 1998).

### 15 **2.4 Heath-risk assessment**

16 Regarding the lung cancer risk via the inhalation route, WHO suggested the unit risk of  
 17  $8.7 \times 10^{-2} (\mu\text{g}/\text{m}^3)^{-1}$  for the lifetime (70 years) PAHs exposure, assuming one exposed to one unit  
 18 BaP concentration (i.e.,  $1 \mu\text{g}/\text{m}^3$ ) (WHO, 1987). It worth noting above unit risk was proposed to  
 19 estimate the lung cancer risk caused by the lifetime exposure, therefore, it has been adopted by a  
 20 recent study for assessing the lung cancer risks of general adults exposure to the ambient  
 21 atmospheric PAHs (Zmirou et al., 2000). For occupational exposure, Pott (1985) established a  
 22 relationship between BaP exposure and lung cancer risk based on a data bank provided by an  
 23 epidemiological study conducted by Redmond et al (1976). He suggested a unit risk of  $7.0 \times 10^{-2}$   
 24  $(\mu\text{g}/\text{m}^3)^{-1}$  for a 25 years occupational PAHs exposure with an averaged BaP concentration of 1  
 25  $\mu\text{g}/\text{m}^3$ . By using the same data bank, the US EPA, however, suggested a different unit risk of



1  $6.4 \times 10^{-4} (\mu\text{g}/\text{m}^3)^{-1}$  for PAHs exposure based on its total PAH content (expressed as the benzene  
2 soluble fractions) (US EPA, 1984). Since a recent study has indicated BaP could be a better  
3 indicator than total PAH content on characterizing the carcinogenic potency of PAHs (Petry et al.,  
4 1996), the unit risk suggested by Pott (1985) was used in this study. In addition, to directly adopt  
5 the above unit risk, the period of 25 years occupational exposure was used in estimating workers'  
6 lung cancer risks accordingly.

7 To estimate the skin cancer risk posed by 25 years occupational dermal PAHs exposure, a  
8 unit risk  $37.47(\text{mg}/\text{kg bodyweight}/\text{day})^{-1}$  suitable for low dose exposures (such as environmental  
9 and occupational exposures) was adopted in this study, assuming personal averaged BaP exposure  
10 level was  $1 \text{ mg}/\text{kg bodyweight}/\text{day}$  (Hussain et al., 1998). The use of the above unit risk in the  
11 present study is because the above value was obtained by extrapolating the lifetime risks from  
12 high doses to low doses by using the Model-Free Extrapolation (MFX) computer model,  
13 assuming a linear dose-response curve at low doses (Krewski et al., 1991).

### 14 **3. Results and Discussion**

#### 15 **3.1 Personal inhalatory PAH exposures**

16 In this study, we found that the mean individual and total PAH exposure concentrations of gas  
17 phase, particle phase and gas+particle phase for all selected threading workers were log-normally  
18 distributed ( $p < 0.001$ , W-test). The above result suggests that the selected threading workers can  
19 be regarded as a similar exposure group (Mulhausen and Damiano, 1998). Table 3 shows the  
20 estimated mean and its corresponding  $\text{LCL}_{1,95\%}$  and  $\text{UCL}_{1,95\%}$  PAH exposure concentrations of  
21 gas phase, particle phase and gas+particle phase for threading workers. We found that the mean  
22 gas phase total PAH exposure level ( $8.60 \times 10^4 \text{ ng}/\text{m}^3$ ) was much higher than that of particle phase  
23 ( $2.30 \times 10^3 \text{ ng}/\text{m}^3$ ). By examining PAH homologue distributions for both gas-phase and  
24 particle-phase PAHs, it can be seen that the fractions of LMW-, MMW- and HMW-PAHs for the  
25 former were 97.2%, 2.5%, and 0.3%, and for the latter were 66.8%, 18.3%, and 14.9%,  
26 respectively. Gas-phase PAHs had a higher fraction in LMW-PAHs was because of their intrinsic

1 high volatility nature. To the contrary, particle-phase PAHs had a higher fraction in both  
2 MMW-PAHs and HMW-PAHs was simply because of their low volatility nature.

3 Table 3 also shows that gas and particle phase total PAH exposures account for 97.4% and  
4 2.6% of workers' inhalatory (i.e., gas + particle phase) PAH exposures, respectively. But for total  
5 BaP<sub>eq</sub> exposure levels, the gas phase ( $1.08 \times 10^2 \text{ ng/m}^3$ ) was lower than that of particle phase  
6 ( $1.18 \times 10^2 \text{ ng/m}^3$ ) accounting for 46.1% and 53.9% of inhalatory exposures ( $2.34 \times 10^2 \text{ ng/m}^3$ ),  
7 respectively. The above results were because gas phase PAHs were dominated by PAHs with  
8 lower TEFs (i.e., LMW-PAHs; see Table 2), but particle-phase PAHs were dominated by PAHs  
9 with higher TEFs (i.e., MMW-PAHs and HMW-PAHs; see Table 2).

10 The present study also shows that workers' mean inhalatory exposure level ( $=8.83 \times 10^4 \text{ ng/m}^3$ )  
11 was lower than the time-weighted average permissible exposure level (PEL-TWA) regulated in  
12 Taiwan for PAHs ( $=1.00 \times 10^5 \text{ ng/m}^3$ ). However, it also can be seen that the corresponding  
13 UCL<sub>1,95%</sub> ( $1.02 \times 10^5 \text{ ng/m}^3$ ) was slightly higher than the above PEL-TWA indicating that PAH  
14 exposures of threading workers might not be negligible. In our previous study, we found that the  
15 mean oil mist exposure concentration of threading workers ( $=2.11 \text{ mg/m}^3$ ) was much lower than  
16 the current PEL-TWA for oil mists ( $=5.0 \text{ mg/m}^3$ ) (Chen et al., 2007). Based on the results  
17 obtained from the present study, it clearly indicates the inadequacy in assessing workers'  
18 inhalatory exposures if only oil mist concentrations were measured.

### 19 **3.2 Personal dermal PAH exposures**

20 Table 4 shows both the total PAHs and total BaP<sub>eq</sub> dermal exposure levels for the whole  
21 body surface area ( $DE_{total,whole}$ ) and each individual body surface ( $UDE_{total,j}$ ). Results show that  
22 the mean  $DE_{total,whole}$  in total PAHs and total BaP<sub>eq</sub> were  $5.44 \times 10^6$  and  $3.71 \times 10^5 \text{ ng/day}$ ,  
23 respectively. Among the estimated mean  $UDE_{total,j}$  (range=  $1.34 \times 10^4 - 7.38 \times 10^4 \text{ ng/100cm}^2/\text{day}$ ),  
24 the top five exposed surface areas were lower arm, hand, upper arm, neck, and head/front with  
25 exposure levels of  $7.38 \times 10^4$ ,  $5.41 \times 10^4$ ,  $3.24 \times 10^4$ ,  $2.48 \times 10^4$ , and  $2.33 \times 10^4 \text{ ng/100cm}^2$ , respectively.  
26 Clearly, the above high exposure levels were mainly because their surface areas were uncovered

1 (or partly uncovered) by clothes, and they are closer to the emission source than other body  
2 surface areas. Here, it should be noted that the exposure level of hand was lower than that of  
3 upper arm was because the latter was covered by cotton gloves. On the other hand, we found that  
4 those six surface areas covered by clothes (i.e., head/back, chest/abdomen, back, upper leg, lower  
5 leg, and foot) had lower exposure levels (range=  $1.34 \times 10^4$ – $2.29 \times 10^4$  ng/100cm<sup>2</sup>) than the above  
6 five surface areas. The same trend can also be seen in dermal total-BaP<sub>eq</sub> exposure levels for each  
7 individual body surface (Table 4).

8 In this study we also found that the fractions of LMW-, MMW-, and HMW-PAHs in  
9 DE<sub>total,whole</sub> (=70.3%, 21.4%, and 8.3%, respectively; data not shown in Table 4) was quite similar  
10 to that of inhalatory particle phase PAH exposures (=68.8%, 18.3%, and 14.9%, respectively;  
11 Table 3), but was very different from that of inhalatory gas phase (=97.2%, 2.5%, and 0.3%,  
12 respectively; Table 3) and gas +particle phase PAHs (96.4%, 2.9%, 0.7%, respectively; Table 3).  
13 The above results suggest airborne particle phase PAHs was the main contributor for dermal PAH  
14 exposures. Considering those body surface areas uncovered (or partly uncovered) by clothes had  
15 higher exposure levels, it implies that the impaction of PAHs-containing oil mists on the  
16 uncovered body surface areas might play the important role on workers' dermal exposures.

### 17 **3.3 Health-risk assessments for both inhalatory and dermal PAH exposures**

18 In this study, workers' total BaP<sub>eq</sub> levels were used to estimate the mean, and its  
19 corresponding LCL<sub>1,95%</sub> and UCL<sub>1,95%</sub> lifetime lung cancer risks for the studied exposure group.  
20 As shown in Table 5, the estimated mean lifetime lung cancer risk ( $1.64 \times 10^{-2}$ ) was contributed  
21 more by particle phase PAH exposures ( $8.81 \times 10^{-3}$ ) than by gas phase PAH exposures ( $7.55 \times 10^{-3}$ ).  
22 However, it should be noted that in this study particle phase PAHs was vigorously extracted by  
23 using a solvent solution (i.e., a mixture of n-hexane and dichloromethane), which could be very  
24 different from that could be extracted in the respiratory system. Particularly, it is expected that the  
25 health risk associated with particle phase PAH exposures could be overestimated. At this stage,  
26 the elution rate of particle-phase PAHs deposited in lung still remains unknown which warrants

1 the need for further investigation in the future.

2 Table 5 also shows the estimated mean (and its corresponding  $LCL_{1,95\%}$  and  $UCL_{1,95\%}$ )  
3 lifetime skin cancer risk for the selected threading workers. To date, the desorption rate of PAHs  
4 for oil mists deposited on the skin surface still remains unknown. However, US EPA (1992) has  
5 suggested a maximum of 20% of PAHs that adsorbed onto soil could be desorbed onto the skin in  
6 24 hours. The above value was adopted in this study. Assuming the body weight of the standard  
7 man (=70 kg) is representative to all threading workers and all of them will be exposed to oil  
8 mists for 25 years (5 days per week, 50 weeks per year) during an average life span of 70 years.  
9 The resultant mean and its corresponding  $LCL_{1,95\%}$  and  $UCL_{1,95\%}$  lifetime dermal total  $BaP_{eq}$   
10 exposure levels for the threading workers were  $2.59 \times 10^{-1}$ ,  $1.77 \times 10^{-1}$ , and  $4.48 \times 10^{-1}$   $\mu\text{g}/\text{kg}/\text{day}$ ,  
11 respectively. The unit risk ( $37.47 \times 10^{-3} (\mu\text{g}/\text{kg} / \text{day})^{-1}$ ) suggested by Hussain et al. (1998) was  
12 adopted in this study to estimate the lifetime skin cancer risk. The estimated mean and its  
13 corresponding  $LCL_{1,95\%}$  and  $UCL_{1,95\%}$  lifetime skin cancer risks were  $9.72 \times 10^{-3}$ ,  $6.64 \times 10^{-3}$ , and  
14  $1.68 \times 10^{-2}$ , respectively. Although the resultant mean lifetime skin cancer risks ( $9.72 \times 10^{-3}$ ) was  
15 slightly lower than that of the mean lifetime lung cancer risk ( $1.64 \times 10^{-2}$ ), both are higher than the  
16 significant risk level ( $10^{-3}$ ) defined by the US Supreme Court in 1980. Therefore, it is  
17 recommended that measurements should be taken in order to reduce both inhalatory and dermal  
18 exposures.

19 Considering PAHs contained oil mists contributed to not only inhalatory but also dermal  
20 exposures, the installation of local exhaust ventilation systems at the emission source (i.e., the  
21 threading machine) should be considered as the first priority measurement because both lung and  
22 skin cancer risks can be reduced simultaneously. On the other hand, if the personal protection  
23 equipment will be adopted for exposure abatement purpose, both respiratory protection equipment  
24 and protective clothing should be used simultaneously from the health risk management aspect.

#### 25 **4. Conclusions**

26 We found that the inhalatory gas-phase total PAHs exposure level was much higher than that

1 of particle-phase. By combining both gas- and particle-phase total PAHs, workers' mean  
2 inhalatory exposure level was lower, but its corresponding  $UCL_{1,95\%}$  was slightly higher than the  
3 PEL-TWA for PAHs. On the other hand, in our previous study we found that workers' mean oil  
4 mist exposure concentration was much lower than the current PEL-TWA for oil mist. The present  
5 study clearly indicates the inadequacy in assessing workers' inhalatory exposures if only oil mist  
6 concentrations were measured. For workers' dermal exposures, the top five exposed surface areas  
7 were lower arm, hand, upper arm, neck, and head/front mainly because their surface areas were  
8 uncovered (or partly uncovered) by clothes. The estimated lifetime lung cancer risk caused by  
9 inhalatory PAH exposures was higher than that of skin cancer risks caused by dermal exposures.  
10 However, both cancer risks are higher than the significant risk level defined by the US Supreme  
11 Court in 1980. Therefore, it is recommended that measurements should be taken in order to  
12 reduce both inhalatory and dermal exposures. The installation of local exhaust ventilation systems  
13 at the emission source should be considered as the first priority measurement because both lung  
14 and skin cancer risks can be reduced simultaneously. If the personal protection equipment would  
15 be adopted in the future, both respiratory protection equipment and protective clothing should be  
16 used simultaneously from the health risk management aspect.

## 17 **Acknowledgment**

18 The authors wish to thank National Science Council in Taiwan for funding this research project.

## 19 **References**

- 20 Attfield MD, Hewett P. Exact expressions for the bias and variance of estimators of the mean of a  
21 lognormal distribution. *Am Ind Hyg Asso J* 1992;53:423–435.
- 22 Bingham E, Horton AW. Environmental carcinogenesis experimental observations related to  
23 occupational cancer. *Adv Biol Skin* 1969;7:183–193.
- 24 Chen YC, Lee WJ, Uang SN, Lee SH, Tsai PJ. Characteristics of Polycyclic Aromatic  
25 Hydrocarbon (PAH) Emissions from a UH-1H Helicopter Engine and Its Impact on the

- 1 Ambient Environment. *Atm Environ* 2006;40:7589–7597.
- 2 Chen MR, Tsai PJ, Chang CC, Shih TS, Lee WJ, Liao PC. Particle size distributions of Oil Mists  
3 in Workplace Atmospheres and Their Exposure Concentrations to Workers in a Fastener  
4 Manufacturing Industry. *J Haz Mater* 2007;146:393–398.
- 5 Chu M, Chen C. Evaluation and estimation of potential carcinogenic risks of polynuclear  
6 aromatic hydrocarbons. Paper presented at the symposium on polycyclic aromatic  
7 hydrocarbons in the workplace. Pacific Rim Risk Conference, Honolulu; 1984.
- 8 Cullen MR, Balmes JR, Robins JM, Smith G.JW. Lipoid pneumonia caused by oil mist exposure  
9 from a steel rolling tandem mill. *Am J Ind Med* 1981;2:51–58.
- 10 Elovaara E, Heikkila P, Pyy L, Mutanen P, Riihimaki V. Significance of dermal and respiratory  
11 uptake in creosote workers: exposure to polycyclic aromatic hydrocarbons and urinary  
12 excretion of 1-hydroxypyrene. *Occup Environ Med* 1995;52:196–203.
- 13 Gilbert RO. *Statistical Methods for Environmental Pollution Monitoring*. New York: Van  
14 Nostrand Reinhold, 1987.
- 15 Granella M, Clonfero E. The mutagenic activity and polycyclic aromatic hydrocarbon compound  
16 content of mineral oils. *Int Arch Occup Environ Health* 1991;63:149–153.
- 17 Hussain M, Rae J, Gilman A, Kauss P. Lifetime health-risk assessment from exposure of  
18 recreational users to polycyclic aromatic hydrocarbons. *Arc Environ Contam Tox*  
19 1998;35:527–531.
- 20 Jarvholm B, Bake B, Lavenius B, Thiringer G, Vokmann R. Respiratory symptoms and lung  
21 function in oil mist-exposed workers. *J Occup Med* 1982;24:473–479.
- 22 Jongeneelen FJ, Scheepers PJF, Groenendijk A, Van Aerts LA, Anzion RBM, Bos RP, Veestra SJ.  
23 Airborne concentrations, skin contamination, and urinary metabolite excretion of polycyclic  
24 aromatic hydrocarbons among paving workers exposed to coal tar derived road tars. *Am Ind*  
25 *Hyg Asso J* 1988;49:600–607.
- 26 Kazerouni N, Thomas TL, Petralia SA, Hayes RB. Mortality among workers exposed to cutting

1 oil mist: update of previous reports. *Am J Ind Med* 2000;38:410–416.

2 Kennedy SM, Chan YM, Teschke K, Karlen B. Change in airway responsiveness among  
3 apprentices exposed to metalworking fluids. *Am J Respir Crit Care Med* 1999;159:87–93.

4 Krewski D, Gaylor D, Szyzkowicz M. A model-free approach to low-dose extrapolation. *Environ*  
5 *Health Perspect* 1991;90:279–285.

6 Lee WJ, Chao WH, Shih ML, Tsai CH, Chen TCH, Tsai PJ. Emissions of Polycyclic Aromatic  
7 Hydrocarbons from Batch Hot Mix Asphalt Plants. *Environ Sci Technol* 2004;38: 5274–5280.

8 Li CT, Lin YC, Lee WJ, Tsai PJ. Emissions of Polycyclic Aromatic Hydrocarbons and Their  
9 Carcinogenic Potencies from Cooking Sources to the Atmosphere of the Urban Area. *Environ*  
10 *Health Perspect* 2003;111:483–487.

11 Lin YC, Lee WJ, Li HW, Chen CB, Fang GC, Tsai PJ. Impact of Using Fishing Boat Fuel with  
12 High Poly-Aromatic Content on the Emission of Polycyclic Aromatic Hydrocarbons from the  
13 Diesel Engine. *Atm Environ* 2006;40:1601–1609.

14 London MA, Boiano JM, Lee SA. Exposure assessment 3,3'-dichlorobenzidine (DCB) at two  
15 chemical plants. *App Ind Hyg* 1989;4:101–104.

16 Massin N, Bohadana AB, Wild P, Goutet P, Kirstetter H, Toamain JP. Airway responsiveness,  
17 respiratory symptoms, and exposures to soluble oil mist in mechanical workers. *Occup*  
18 *Environ Med* 1996;53:748–752.

19 Michalek DJ, Hii WWS, Sun JS, Gunter KL. Experimental and analytical efforts to characterize  
20 cutting fluid mist formation and behavior in machining. *Appl Occup Envir Hyg*  
21 2003;18:842–854.

22 Moulin JJ, Wild P, Fourmier-Betz B, Mur JM, Smagghe G. Mortality from lung cancer and  
23 cardiovascular disease among stainless steel-producing workers. *Cancer Causes Control*  
24 1993;4:75–81.

25 Mulhausen JR, Damiano J. *A Strategy for Assessing and Managing Occupational Exposures*,  
26 Fairfax: American Industrial Hygiene Association (AIHA), 1998.

- 1 Nisbet C, LaGoy P. Toxic equivalency factors (TEFs) for polycyclic aromatic hydrocarbons  
2 (PAHs). *Reg Tox Pharmacol* 1992;16:290–300.
- 3 Petry T, Schmid P, Schlatter C. The use of toxic equivalency factors in assessing occupational and  
4 environmental health risk associated with exposure to airborne mixtures of polycyclic  
5 aromatic hydrocarbons (PAHs). *Chemosphere* 1996;32:639–648.
- 6 Pott F. Pyrolyseagase, PAH und lungenkrebrisiko-daten und bewertung. *Staub-Reinhaltung dedr*  
7 *Luft* 1985;45:368–379.
- 8 Rappaport SM. Assessment of long-term exposures to toxic substances in air. *Ann Occup Hyg*  
9 1991;35:61–121.
- 10 Redmond C, Strobino B, Cypess R. Cancer experience among coke by-product workers. *Ann NY*  
11 *Acad Sci* 1976;217:102–115.
- 12 Robertson AA, Weir DC, Burge PS. Occupational asthma due to oil mists. *Thorax* 1988;43:  
13 200–205.
- 14 Roy TA, Johnson SW, Blackburn GR, Merkerer CR. Correlation of mutagenic and dermal  
15 carcinogenic activities of mineral oils with polycyclic aromatic hydrocarbon compound  
16 content. *Appl Toxicol* 1988;10:466–476.
- 17 Russi M, Dubrow R, Flannery JT, Cullen MR, Mayne ST. Occupational exposure to machining  
18 fluids and laryngeal cancer risk: contrasting results using two separate control groups. *Am J*  
19 *Ind Med* 1997;31:166–171.
- 20 Thornburg D. Leith, Mist generation during metal machining. *J Trib* 2000;122:544–549.
- 21 Thorslund T, Farrer D. Development of relative potency estimated for PAHs and hydrocarbon  
22 combustion product fractions compared to benzo(a)pyrene and their use in carcinogenic risk  
23 assessments. US Environmental Protection Administration (EPA), Washington DC; 1991.
- 24 Tsai PJ, Hsieh HY, Lee WJ, Lai SO. Health-risk assessment for workers exposed to polycyclic  
25 aromatic hydrocarbons in a carbon black manufacturing industry. *Sci Total Environ*  
26 2001;278:137–150.



1 Tsai PJ, Shieh HY, Hsieh LT, Lee WJ. The Fate of PAHs in the Carbon Black Manufacturing  
2 Process. *Atmospheric Environment* 2001;35:3495–3501.

3 Tsai PJ, Shih TS, Chen SL, Lee WJ, Lai GH, Liou SH. Assessing the Contents of Polycyclic  
4 Aromatic Hydrocarbons in the Tollbooths of a Highway Toll Station via Direct and Indirect  
5 Approaches. *Environ Sci Technol* 2002;36:4748–4753.

6 Tsai PJ, Shih TS, Chen SL, Lee WJ, Lai GH, Liou SH. Assessing and Predicting the Exposures of  
7 Polycyclic Aromatic Hydrocarbons (PAHs) and Their Carcinogenic Potencies from Vehicle  
8 Engine Exhausts to Highway Toll Station Workers. *Atm Environ* 2004;38:333–343.

9 US EPA. Health effects assessments for polycyclic aromatic hydrocarbons (PAHs). US  
10 Environmental Protection Agency (EPA), Environmental Criteria and Assessment Office, EPA  
11 549/1-86-013, Cincinnati; 1984.

12 US EPA. Pesticide assessment guideline, subdivision U, applicator exposure monitoring. US  
13 Environmental Protection Administration (EPA), U.S. Department of Commerce, National  
14 Technical Information Service, Springfield; 1987.

15 US EPA. Dermal exposure assessment: principles and applications. US Environmental Protection  
16 Administration (EPA), EPA/600/8-91/011B, Washington DC; 1992.

17 Verma DK, Julian JA, Roberts RS, Muir DC, Jadon N, Shaw DS. Polycyclic aromatic  
18 hydrocarbons (PAHs): a possible cause cause of lung cancer mortality among nickel/copper  
19 smelter and refinery workers. *Am Ind Hyg Assoc J* 1992;53:317–324.

20 WHO. World Health Organization field surveys of exposure to pesticide protocol. *Tox Letter*  
21 1986;33:223–235.

22 WHO. Air quality guideline for Europe. WHO European Series, WHO Regional Bureau,  
23 Copenhagen; 1987.

24 Zmirou D, Masclat P, Boudet C, Dor F, Dēchenaux J. Personal exposure to atmospheric  
25 polycyclic aromatic hydrocarbons in a general adult population and lung cancer risk  
26 assessment. *J Occup Environ Health* 2000;42:121-125.



1 **Table Captions**

2 Table 1 Representative dermal sampling body sites and their corresponding body surface areas  
3 as recommended by U.S. EPA (1987), and the sampling spots that selected in this study

4 Table 2 PAHs and their toxic equivalent factors (TEFs) suggested by Nisbet and LaGoy in 1992

5 Table 3 Exposure concentrations of 22 selected PAH compounds, LMW-PAHs, MMW-PAHs,  
6 HMW-PAHs, total PAHs and total BaP<sub>eq</sub> for threading workers

7 Table 4 Unit total PAHs and total BaP<sub>eq</sub> exposure concentrations for the 11 selected body surface  
8 areas ( $UDE_{total,j}$ ; ng/100cm<sup>2</sup>/day) and total PAHs and total BaP<sub>eq</sub> exposure concentrations  
9 for the whole body surface area ( $DE_{total,whole}$ ; ng/day)

10 Table 5 Estimated cancer risk associated with both inhalatory and dermal PAH exposures for  
11 threading workers